Recherche
-
Coronary Events After Dispensing of Ibuprofen: A Propensity Score-Matched Cohort Study Versus Paracetamol in the French Nationwide Claims Database Sample
(Drug Safety. vol. 41, n° 11, pp. 1049-1058, 2018-11)Article de revue -
Patterns of quadruple therapy use including bismuth for Helicobacter pylori eradication: A cohort study in the French national claims database
(Thérapie. vol. 76, n° 5, pp. 435-440, 2021-09)Article de revue -
Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDS
(Am J Cardiovasc Drugs. vol. 20, n° 1, pp. 81-103, 2020)Article de revue -
Does Ibuprofen Worsen COVID-19?
(Drug Safety. vol. 43, n° 7, pp. 611-614, 2020)Article de revue -
Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database
(Atherosclerosis. vol. 281, pp. 98-106, 2019)Article de revue -
Pharmacovigilance - The next chapter
(Thérapie. vol. 74, n° 6, pp. 557-567, 2019-12)Article de revue -
Effectiveness and safety of 110 or 150 mg dabigatran vs. vitamin K antagonists in nonvalvular atrial fibrillation
(British Journal of Clinical Pharmacology. vol. 85, n° 2, pp. 432-441, 2019)Article de revue -
Diagnostic accuracy of the International Classification of Diseases, Tenth Revision, codes of heart failure in an administrative database
(Pharmacoepidemiology and Drug Safety. vol. 28, n° 2, pp. 194-200, 2019)Article de revue -
Effectiveness and Safety of Standard and Reduced Doses of Dabigatran Compared to Rivaroxaban in Nonvalvular Atrial Fibrillation: Long-Term Results from a Cohort Study in the French Nationwide Claims Database
(Journal of the American College of Cardiology. vol. 75, n° 11, pp. 357, 2020)Article de revue -
Empirical assessment of case-based methods for identification of drugs associated with upper gastrointestinal bleeding in the French National Healthcare System database (SNDS)
(Pharmacoepidemiology and Drug Safety. vol. 29, n° 8, pp. 890-903, 2020)Article de revue